培美曲塞治疗复发性卵巢癌的疗效观察

发布时间：2018-11-19 14:35

【摘要】：目的评估培美曲塞治疗复发性卵巢癌的临床效果。方法选取2013年1月-2014年12月于南通大学附属医院接受治疗的90例复发性卵巢癌患者作为研究对象,依据随机数字表方法将其分为对照组(n=40)与观察组(n=50)两组,对照组给予紫杉醇联合伊立替康治疗,观察组则应用培美曲塞治疗方案,对比观察两组患者的临床疗效及腹水控制率。结果观察组总有效率66.0%、腹水控制率82.0%,对照组总有效率35.0%、腹水控制率47.5%,组间比较,差异有统计学意义(P0.05);两组不良反应发生率分别为38.0%和42.5%,组间比较,差异无统计学意义(P0.05);两组治疗后糖类抗原125、人肿瘤坏死因子α、可溶性白细胞介素2受体及人附睾蛋白4指标比较,差异有统计学意义(P0.05)。结论在复发性卵巢癌患者的临床治疗中,用培美曲塞方案疗效好、安全性高,值得推广。
[Abstract]:Objective to evaluate the clinical effect of pemetrexil in the treatment of recurrent ovarian cancer. Methods from January 2013 to December 2014, 90 patients with recurrent ovarian cancer who were treated in Nantong University Hospital were divided into two groups: control group (n = 40) and observation group (n ~ (50). The control group was treated with paclitaxel combined with irinotecan while the observation group was treated with pemetrexil. The clinical efficacy and ascites control rate were compared between the two groups. Results the total effective rate of the observation group was 66.0 and the ascites control rate was 82.0. The total effective rate of the control group was 35.0 and the ascites control rate was 47.5. The difference between the two groups was statistically significant (P0.05). The incidence of adverse reactions in the two groups was 38.0% and 42.5% respectively. There was no significant difference between the two groups (P0.05). There were significant differences in carbohydrate antigen 125, tumor necrosis factor 伪, soluble interleukin 2 receptor and human epididymis protein 4 between the two groups (P0.05). Conclusion in the clinical treatment of recurrent ovarian cancer, the pemetrexed regimen has good efficacy and high safety, and is worth popularizing.
【作者单位】：南通大学附属医院化疗科;南通大学附属医院妇产科;
【分类号】：R737.31

【相似文献】